Shares of Theravance (UNKNOWN:THRX.DL), a healthcare royalty management company for a focus on respiratory products, were down big during September after the company and its partner GlaxoSmithKline PLC (NYSE:GSK) released disappointing clinical news.

Are the shares a buy after the fall? See the presentation below for details.